Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
META-1 anti-PD-1 monotherapy in first-line advanced NSCLC with high PD-L1 and PTI=0
2025-522655-26-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and cemiplimab in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Unicancer. Primary endpoint: 12-week non-progression rate. Planned start Jul 2026; status: authorised.
02
Drugs
pembrolizumabcemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-522655-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522655-26-00.